Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.90 Insider Own3.28% Shs Outstand29.81M Perf Week-0.77%
Market Cap17.01M Forward P/E- EPS next Y-0.84 Insider Trans0.00% Shs Float28.83M Perf Month-2.88%
Income-26.27M PEG- EPS next Q-0.22 Inst Own7.22% Short Float / Ratio1.03% / 1.88 Perf Quarter46.12%
Sales0.00M P/S- EPS this Y12.87% Inst Trans0.36% Short Interest0.30M Perf Half Y-12.82%
Book/sh1.18 P/B0.48 EPS next Y4.92% ROA-50.09% Target Price9.50 Perf Year-56.77%
Cash/sh0.82 P/C0.69 EPS next 5Y- ROE-56.16% 52W Range0.34 - 1.65 Perf YTD-46.17%
Dividend- P/FCF- EPS past 5Y20.36% ROI-73.72% 52W High-65.42% Beta1.94
Dividend %- Quick Ratio7.10 Sales past 5Y0.00% Gross Margin- 52W Low68.97% ATR0.05
Employees19 Current Ratio7.10 Sales Q/Q- Oper. Margin0.00% RSI (14)52.49 Volatility5.98% 9.90%
OptionableNo Debt/Eq0.02 EPS Q/Q37.43% Profit Margin- Rel Volume0.32 Prev Close0.59
ShortableYes LT Debt/Eq0.01 EarningsNov 13 BMO Payout- Avg Volume157.58K Price0.57
Recom1.00 SMA200.48% SMA5010.34% SMA200-14.78% Volume53,606 Change-3.29%
Date Action Analyst Rating Change Price Target Change
Jul-18-22Resumed Oppenheimer Outperform $14
Nov-14-23 01:46PM
Nov-13-23 08:05AM
Nov-07-23 08:45AM
08:35AM Loading…
Nov-06-23 08:35AM
Oct-24-23 07:45AM
Oct-18-23 10:00AM
Oct-11-23 09:05AM
Oct-02-23 08:40AM
Sep-22-23 07:58AM
Sep-21-23 08:50AM
Sep-18-23 08:40AM
Sep-14-23 08:35AM
Sep-05-23 08:35AM
12:16AM Loading…
Aug-12-23 12:16AM
Aug-11-23 06:45AM
Aug-10-23 04:05PM
Aug-07-23 08:40AM
Aug-03-23 08:45AM
Jul-13-23 08:40AM
Jul-06-23 08:45AM
Jun-13-23 08:35AM
May-30-23 09:05AM
May-12-23 11:15AM
May-11-23 08:04AM
May-10-23 04:05PM
May-04-23 08:35AM
May-02-23 08:35AM
09:55AM Loading…
Apr-24-23 09:55AM
Apr-18-23 05:33PM
Mar-27-23 12:00PM
Mar-24-23 05:33AM
Mar-23-23 07:10AM
Mar-22-23 04:20PM
Mar-21-23 08:50AM
Mar-15-23 08:30AM
Mar-13-23 08:35AM
Mar-09-23 08:35AM
Mar-01-23 08:45AM
Feb-13-23 11:30AM
Jan-11-23 01:00PM
Jan-05-23 08:45AM
Dec-21-22 08:25AM
Dec-19-22 09:15AM
Dec-15-22 01:09PM
Dec-07-22 08:45AM
Nov-14-22 05:23PM
Nov-10-22 04:05PM
Nov-07-22 09:05AM
Oct-14-22 08:40AM
Sep-27-22 01:01PM
Sep-23-22 09:11AM
Sep-08-22 08:45AM
Sep-07-22 08:35AM
Sep-06-22 08:45AM
Aug-19-22 08:40AM
Aug-15-22 08:35AM
Jul-28-22 08:35AM
Jul-11-22 10:22AM
Jul-08-22 08:35AM
Jun-16-22 08:35AM
May-26-22 08:35AM
May-19-22 08:05AM
May-12-22 08:35AM
May-10-22 08:35AM
May-05-22 08:15AM
May-04-22 08:15AM
Apr-21-22 08:47AM
Apr-14-22 08:05AM
Apr-11-22 07:05AM
Apr-08-22 01:05PM
Mar-25-22 07:05AM
Mar-23-22 08:05AM
Mar-11-22 08:05AM
Mar-01-22 08:35AM
Feb-14-22 02:10PM
Feb-01-22 09:11AM
Jan-20-22 08:40AM
Jan-18-22 08:05AM
Jan-12-22 10:35AM
Jan-07-22 08:30AM
Dec-27-21 08:05AM
Dec-01-21 08:35AM
Nov-12-21 08:05AM
Nov-11-21 08:05AM
Nov-04-21 02:30PM
Oct-20-21 05:46PM
Oct-19-21 09:05AM
Oct-18-21 08:25AM
Sep-27-21 07:05AM
Sep-17-21 08:05AM
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.